The aim: Multiple myeloma (MM) is B-cell neoplasm characterized with multifocal malignant plasma cell bone infiltration, while the molecular basis of disease remains unclear. Angiogenesis, biological phenomenon of new blood vessel formation is present in different plasma cellular disorders and is of importance in active MM. Because of that the inhibition of tumour angiogenesis has shown to be promising target in myeloma therapy. The aim of this study was to determine angiogenesis and expression of vascular endothelial growth factor (VEGF), monocyte chemotactic protein (MCP-1) in relation to nuclear factor kappa B (NF-kB) on molecular level, cellular level as well as in plasma of MM patients. Patients and Methods: The study was conducted on 79 patients with diagnosed MM including clinical parameters of stage, therapy response and overall survival. The bone marrow biopsy specimens were used for double immunostaining method for detection of mean vascular density (MVD), Ki67 proliferation index (PI), VEGF, MCP- 1 and subcellular localization of NF-kB. Plasma samples obtained from 19 patients were used for detection of VEGF and MCP-1 using ELISA method, while the bone aspirates were used for magnetic cell labeling or flow cytometry separation in order to separate myeloma cells and determine mRNA VEGF and MCP-1 by RT-PCR. Results: The results have shown positive correlation of MVD, % of bone marrow tumour infiltrate (p<0,001), atypical plasma cell morphology (p=0,001) and clinical stage (p=0,001) the patients were in. Further, there was significant correlation of MVD and poor therapy response (p=0,029) as well as shorter survival (p=0, 04) when high MVD values were observed. The VEGF expression was significantly lower when MVD was higher (p=0,002). The lower expression of both cytokines VEGF (p =0,006) and MCP-1 (p =0, 03) was related to higher NF-êB expression. The higher plasma concentrations of VEGF compared to the control group were observed (p=0.008). Concentration of both cytokines VEGF (p=0.05) and MCP-1(p=0.05) correlated with % of tumour cell infiltrate (p=0.05), while VEGF correlated with the clinical stage (p=0,001), respectively. Values of mRNA VEGF and MCP-1 showed lack of significance when compared with any of parameters in the study. Conclusions: The results of this study confirmed correlation of angiogenesis and poor prognostic parameters in myeloma as well as shorter survival observed. The concentrations of cytokines in blood, VEGF and MCP-1 are in proportion with tumour mass and could be important clinical parameters which remain to be confirmed in further studies. Observed inverse correlation of NF-kB in myeloma cells and angiogenic cytokines does not rule out the possibility of their mutual connection in regulation of synthesis and secretion of these proteins.